- Home
- OFG vs NVCR Comparison
OFG vs NVCR Comparison
Compare OFG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFG | NVCR |
|---|---|---|
| Founded | 1964 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OFG | NVCR |
|---|---|---|
| Price | $52.89 | $15.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $45.17 | $28.08 |
| AVG Volume (30 Days) | 291.7K | ★ 1.7M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 8.27 | ★ 21.79 |
| EPS | ★ 2.64 | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $11.56 | $7.72 |
| Revenue Next Year | $1.29 | $6.74 |
| P/E Ratio | $41.98 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $35.71 | $9.82 |
| 52 Week High | $53.82 | $21.45 |
Technical Indicators
Market Signals| Indicator | OFG | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 47.40 |
| Support Level | $44.15 | $12.85 |
| Resistance Level | N/A | $18.48 |
| Average True Range (ATR) | 1.02 | 1.13 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 77.01 | 12.99 |
Price Performance
Historical ComparisonAbout OFG OFG Bancorp
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.